{
  "id": "fractyl-health-reports-positive-6-month-remain-1-midpoint-data-for-revita",
  "title": "Fractyl Health reports positive 6‑month REMAIN‑1 midpoint data for Revita®",
  "summary": "Fractyl Health, Inc. said interim six‑month randomized data from the REMAIN‑1 Midpoint Cohort indicate that patients treated with its Revita® investigational procedure maintained weight more effectively after discontinuing GLP‑1 weight‑loss drugs compared with a sham control, the company said. Revita‑treated participants experienced approximately 4.5 percent weight regain versus 7.5 percent in the sham group at six months […] The post Fractyl Health reports positive 6‑month REMAIN‑1 midpoint data for Revita® appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/fractyl-health-reports-positive-6-month-remain-1-midpoint-data-for-revita/",
  "source": "Longevity.Technology",
  "author": null,
  "category": "news",
  "publishedAt": "2026-01-31T08:41:06.000Z",
  "fetchedAt": "2026-02-04T10:49:05.817Z",
  "relevanceScore": 0.2,
  "matchedKeywords": [
    "longevity"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.889Z"
}